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Abstract 
 
Background: Low foot ulcer risk in South Asian, compared with European, people with type 2 
diabetes in the UK has been attributed to their lower levels of neuropathy. We have undertaken 
a detailed study of corneal nerve morphology and neuropathy risk factors, to establish the basis 
of preserved small nerve fibre function in South Asians versus Europeans. 
Methods: In a cross-sectional, population-based study, age- and sex-matched South Asians 
(n=77) and Europeans (n=78) with type 2 diabetes underwent neuropathy assessment using 
corneal confocal microscopy, symptoms, signs, quantitative sensory testing, electrophysiology 
and autonomic function testing. Multivariable linear regression analyses determined factors 
accounting for ethnic differences in small fibre damage. 
Results: Corneal nerve fibre length (22.0±7.9 vs. 19.3±6.3 mm/mm2; P=0.037), corneal nerve 
branch density (geometric mean (range): 60.0 (4.7-246.2) vs. 46.0 (3.1-129.2) no./mm2; 
P=0.021) and heart rate variability (geometric mean (range): 7.9 (1.4-27.7) vs. 6.5 (1.5-22.0); 
P=0.044), were significantly higher in South Asians vs. Europeans. All other neuropathy 
measures did not differ, except for better sural nerve amplitude in South Asians (geometric 
mean (range): 10.0 (1.3-43.0) vs. 7.2 (1.0-30.0); P=0.006). Variables with the greatest impact 
on attenuating the P value for age- and HbA1C-adjusted ethnic difference in corneal nerve fibre 
length (P=0.032) were pack-years smoked (P=0.13), BMI (P=0.062) and triglyceride levels 
(P=0.062). 
Conclusions: South Asians have better preserved small nerve fibre integrity than equivalent 
Europeans; furthermore, classic, modifiable risk factors for coronary heart disease are the main 
contributors to these ethnic differences. We suggest that improved autonomic neurogenic 
control of cutaneous blood flow in Asians may contribute to their protection against foot ulcers. 
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Introduction 
Lower limb amputation, as a consequence of foot ulceration, is a major cause of morbidity and 
is associated with a high mortality in type 2 diabetes mellitus, highlighting the importance of 
defining mechanisms and risk factors to enable targeted interventions for improving outcomes. 
It is therefore fascinating that migrant populations of South Asian descent to the UK, with their 
considerably elevated risk of type 2 diabetes and ischemic heart disease1, 2, have substantially 
lower risks of foot ulceration and amputation (3- and 4-fold lower, respectively) compared with 
Europeans3-5. Furthermore, recently the DISTANCE study showed that Asians in general, and 
South Asians in particular, in the US had a markedly reduced risk of lower extremity 
amputation6. The underlying basis for this protection, however, is not clearly understood and 
demonstrates differing pathophysiologies of diabetes according to ethnicity7 
Peripheral neuropathy per se is one of the strongest risk factors for diabetic foot ulceration and 
amputation78-11. We have previously shown that lower levels of clinical neuropathy in Asians 
accounted for approximately half of their reduced risk of foot ulceration5. Furthermore, in a 
population-based sample of UK primary care patients with type 2 diabetes we have also 
demonstrated better large and small fibre function in South Asians vs. Europeans12. Better 
peripheral vascular function and lower smoking rates in South Asians, rather than differences 
in glycaemic control and hyperlipidaemia largely accounted for this difference. 
It is established that small fibre damage precedes large fibre damage in diabetic neuropathy13,14. 
Furthermore, small fibre damage results in loss of pain sensation and autonomic control of 
cutaneous blood flow15,16; both are permissive factors for foot ulceration. Perhaps of relevance, 
we have previously shown that South Asians without ‘clinical neuropathy’ maintained a 50% 
increased risk of painful neuropathy-like symptoms compared with similar Europeans17; this 
could be suggestive of a pathology other than neuropathy in the legs accounting for increased 
 
 
pain in South Asians but may also indicate a greater prevalence of small fibre damage in the 
European cohort.   
Our recent study indicated that South Asian populations with type 2 diabetes have some 
protection against the development of small fibre neuropathy12. There is an increasing body of 
evidence supporting the use of CCM to study small fibre neuropathy, including autonomic 
dysfunction18-20. We hypothesized, therefore, that ethnic differences in small nerve fibre 
function would be supported by differences in corneal nerve fibre morphology and intra-
epidermal nerve fibre density in South Asians compared with Europeans. Furthermore, we 
aimed to determine which risk factors explained these ethnic differences in small nerve fibre 
structure and hence the South Asian protection against foot ulceration. 
Materials and Methods 
Study Subjects 
This is a sub-study of a population-based bi-ethnic cohort of people with type 2 diabetes 
(n=360), half European and half of South Asian descent, recruited from eight primary care 
registers in Manchester, UK12. Participants were randomly selected from within ethnicity, 
gender and age stratified groups to ensure matching for these variables; study participants and 
non-participants were similar for age and gender. European and South Asian groups were 
considered representative ethnic samples of primary care patients with type 2 diabetes in 
Greater Manchester12. All participants consented that they may be re-contacted for follow-up.  
Approximately 4 years (2007-2012) after their initial visit each participant was invited to re-
attend The Wellcome Trust Clinical Research Facility, Manchester, via a postal invitation, for 
a single follow-up visit. Exclusion criteria at follow-up were major lower limb amputation 
(distal symmetrical polyneuropathy assessment required testing in both feet), psychiatric 
disorder, HIV, hepatitis, or terminal illness. Of the 360 original subjects, 81 did not respond to 
the postal invitation and were untraceable; a further 45 had moved away from the health 
 
 
authority and were untraceable; 22 responded negatively and did not wish to participate further, 
28 responded positively, were eligible, but later changed their minds and decided not to 
participate, 1 subject responded positively but was ineligible due to the development of a 
significant psychiatric disorder and 28 had died. No-one was excluded due to lower limb 
amputation. One-hundred and fifty-five individuals re-consented to participate in the follow-
up study (response rate of 43%), with an equal ethnic split (South Asian n=77, European n=78). 
Differences between responders (n=155) and non-responders (n=205) were not significant for 
ethnicity, age, diabetes duration, BMI or HbA1c; however, a higher proportion of men re-
consented (consenters - M: F 95:59; non-consenters - M: F 96:110; P=0.005). This study was 
approved by North Manchester Research Ethics Committee and by the University of 
Manchester Research Ethics Committee and written informed consent was obtained according 
to the declaration of Helsinki. 
Clinical Assessments 
All subjects completed a questionnaire including detailed past medical history, current 
medication and lifestyle factors, including smoking behaviour. Self-assigned ethnicity was 
checked and cross-validated with the country of birth. All South Asians were first generation 
migrants from India, Pakistan or Bangladesh. Height, weight, waist and hip circumference were 
measured once. Triplicate resting blood pressure readings were averaged using a standard 
protocol12. Blood samples were assessed in central laboratories for HbA1c, total cholesterol, 
HDL-cholesterol, triglycerides and fibrinogen.  
Complications Assessment 
Retinopathy and nephropathy were defined as a history of physician diagnosed disease. 
Cardiovascular Disease (CVD) was defined as either a physician diagnosed myocardial 
infarction, angina, or a positive response to the Rose angina questionnaire217. Peripheral arterial 
disease was defined as a previous history of physician diagnosed claudication confirmed by a 
 
 
lower limb arteriogram or a positive response to the Edinburgh claudication questionnaire22. 
Transcutaneous partial pressure of oxygen (TcPO2) was measured on the dorsum of the left 
foot12. 
Assessment of neuropathy  
Neurological symptoms of muscle weakness, sensation and autonomic neuropathy were 
evaluated using the Neuropathy Symptoms and Change validated questionnaire score23 and the 
McGill pain analogue score was used to assess the severity of painful neuropathic symptoms. 
Neurological signs were assessed using the modified neuropathy disability score, evaluating 
vibration, pinprick and temperature perception and ankle reflexes12. Vibration Perception 
Threshold was measured on the tip of the right and left hallux using a Neurothesiometer 
(Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK); mean readings were used 
for analysis. Electrophysiological assessments of peroneal and sural nerves in the right lower 
limb were performed by a Neurophysiologist using a Dantec “Keypoint” electromyography 
system (Dantec Dynamics Ltd, Bristol, UK) with surface electrodes at standardised points (skin 
temperature ≥32°C). 
Small fibre function 
Cold sensation (Aδ fibre) and warm sensation (C fibre) thresholds were determined with the 
MEDOC TSA II (Medoc Ltd., Ramat Yishai 30095, Israel) using the method of limits on the 
dorsum of the left foot, as previously described20. Changes to heart rate variability in response 
to deep breathing (HRV-DB) was determined using the CASE IV system and ECG monitor, 
averaging two separate cycles of deep breathing12. Peripheral cholinergic function (sudomotor 
function) was assessed using the Neuropad, on the plantar skin surface of both feet25.  
Intra Epidermal Nerve Fibre Density  
Skin biopsies were taken in a sub-group of 49 of the 155 patients; this sub-group was matched 
for ethnicity (24 South Asians vs 25 Europeans), age (61.3 ±7.9 vs 62.5 ± 7.8 years), gender 
 
 
(15 men: 9 women vs 20 men: 5 women) and HbA1C (8.0 ± 1.3 vs 7.8 ± 1.4 %). A 3-mm punch 
skin biopsy was taken from the dorsum of the foot and stained with protein gene product 9.5 
to identify and count intra-epidermal nerve fibres and establish intra epidermal nerve fibre 
density, i.e. the number of fibres per millimeter of basement membrane24. 
Corneal Confocal Microscopy 
Participants underwent examination with the Heidelberg Retina Tomograph (HRT III) in vivo 
corneal confocal microscope (IVCCM) using our established protocol26. Several scans of the 
entire depth of the cornea were recorded to provide en face two dimensional images with a 
lateral resolution of approximately 2 µm/pixel and final image size of 400 x 400 pixels of the 
sub-basal nerve plexus of the cornea. Five images per patient from the centre of the cornea 
were selected and examined in a masked and randomised fashion27. Four corneal nerve 
parameters were quantified: (i) Corneal nerve fibre density  - number of major nerves/mm2 of 
corneal tissue; (ii) Corneal nerve branch density  - number of branches emanating from all 
major nerve trunks/mm2 of corneal tissue; (iii) Corneal nerve fibre length - length of all nerve 
fibres and branches (mm/mm2) within the area of corneal tissue; (iv) tortuosity – a 
mathematically derived index of the curvilinear deviation from the midline of each main nerve 
fibre28.  
Statistical Analysis 
Corneal nerve fibre length was selected as the primary corneal nerve outcome to assess small 
nerve fibre structure, as it combines data for both branch and fibre length.  We estimated that 
160 participants (80 in each ethnic group) would be sufficient with 85% power to detect a 
difference in corneal nerve fibre length of at least one-third of SD at the 5% significance level, 
making allowances for missing data. Neuropathy measures were compared between the ethnic 
groups as continuous variables using simple means. Several comparison tests have been carried 
 
 
out and hence the results of these tests should be interpreted as showing an indication of a 
possible difference. 
 Normally distributed data were tested using Student’s t test, non-normally distributed data 
were either log transformed before analysis or the Mann-Whitney test was used. Categorical 
variables were compared as simple proportions and tested using chi-square test for significance. 
Independent statistically significant variables for the neuropathy outcomes were found using a 
backward stepwise selection procedure in the multivariable regression models. Ethnicity and 
other neuropathy risk factors (duration of diabetes, HbA1C, triglycerides, BMI) were considered 
for selection. 
Multivariable linear regression models were constructed to investigate the effect of potential 
confounders previously shown to be associated with neuropathy, including glycaemic control, 
height, smoking, measures of hypertension, obesity and hyperlipidaemia and determine which 
factors could account for any ethnic differences in neuropathy measures. 
Sensitivity analyses were performed to examine the data further. Generalised additive models 
(GAMs) were used to investigate if any of the covariates required a more complex relationship 
than linear with the outcome. These analyses were performed in R version 3.1. Heckman 
selection models were used to determine if there was selection bias that affected the outcome 
models and was implemented in Stata 13. All other analyses were performed using SPSS 20 or 
22 (IBM). 
 
 
 
 
Results 
We studied 155 people with type 2 diabetes (4.9±0.6 years post original visit) comprising 77 
South Asians and 78 Europeans. South Asians were younger (P=0.047) and had a (close to 
significantly) longer duration of diabetes (P=0.063) than Europeans (Table 1). South Asians 
were shorter (P=0.046) and had a lower BMI (P<0.001). There was no significant difference 
in the prevalence of clinically evident CVD or retinopathy and nephropathy. There was no 
difference in systolic and diastolic blood pressure; antihypertensive therapy use was lower in 
South Asians (P=0.044). Total cholesterol and HDL-cholesterol were comparable but 
triglyceride levels (P=0.001) were lower in South Asians; a lower percentage of South Asians 
used statins but the difference was not significant (p=0.074). South Asians had a higher HbA1c 
(P=0.016). 
Clinical signs and symptoms 
There was no difference in neuropathy disability score or vibration perception threshold 
between Europeans and South Asians (Table 2) and both groups had evidence of mild 
neuropathy. Painful diabetic neuropathy (significant signs plus at least one positive sensory 
symptom) did not differ between the groups, however painful neuropathy-like symptoms in the 
absence of clinical neuropathy (no signs but at least one positive sensory symptom) were more 
prevalent in South Asians (P=0.018).  
Neurophysiology  
Peroneal nerve conduction velocity, amplitude and F wave latency did not differ significantly 
between groups. Sural nerve conduction velocity was comparable but South Asians had a 
significantly higher sural nerve amplitude (µA) than Europeans (geometric mean (range): 10.0 
(1.3-43.0) vs 7.2 (1.0-30.0), P=0.006) (Table 2). 
Small nerve fibre function 
 
 
Thermal threshold assessments: cold sensation (median, IQR: 25.9, 23.1-27.7 vs. 25.6, 22.9-
27.2), warm sensation (41.6±4.2 vs. 42.0±3.8), cold-induced pain (median, IQR: 1.9, 0-9.4 vs. 
1.3, 0-5.9) and heat-induced pain (median, IQR: 49.1, 46.8-50.0 vs. 49.0, 47.4-49.9) did not 
differ between South Asian and European participants (Table 2). There was no significant 
difference for the Neuropad response (%) (median, IQR: 68.8, 30.6-95.0 vs. 55.0, 15.0-87.5) 
between South Asians and Europeans. Heart rate variability to deep breathing (HRV-DB) 
(beats/min) (geometric mean (range): 7.9 (1.4-27.7) vs 6.5 (1.5-22.0), P=0.044) was 
significantly higher in South Asians compared with Europeans. 
Small nerve fibre structure  
Intra epidermal nerve fibre density was slightly higher in South Asian participants than in 
European participants, though the difference was not statistically significant (Table 2). Corneal 
nerve fibre density and tortuosity were comparable between the ethnic groups. However, both 
corneal nerve fibre length (mm/mm2) (22.0±7.9 vs. 19.3±6.3; P=0.037) and corneal nerve 
branch density (no./mm2) (geometric mean (range): 60.0 (4.7-246.2) vs. 46.0 (3.1-129.2); 
P=0.021) were significantly higher in South Asians than Europeans (Table 2). 
 
Multivariable stepwise regression analyses established that ethnicity (P=0.032), age (P=0.004) 
and HbA1C (P<0.001) were independent statistically significant risk factors for corneal nerve 
fibre length (Table 3). The exact same variables were risk factors for corneal nerve branch 
density (ethnicity P=0.026, age P=0.007, HbA1C P=0.011). The independent statistically 
significant risk factors for sural nerve amplitude were ethnicity (P=0.006), age (P<0.001) and 
duration of diabetes (P=0.003). Age (P<0.001) and hypertensive therapy (P=0.003) were 
independently significant for heart rate deep breathing but ethnicity was not statistically 
significant (Table 4). 
Explanations for ethnic differences in corneal nerve fibre structure. 
 
 
Multivariable analyses were used to explore the role of neuropathy risk factors, i.e. glycaemic 
control, height, smoking, vascular function, measures of hypertension, obesity and 
hyperlipidaemia as potential explanations for the ethnic difference in corneal nerve fibre length 
(Table 3). The variables with the greatest impact on attenuating the P value for the age- and 
HbA1C-adjusted ethnic difference in corneal nerve fibre length (P=0.032) were BMI (P=0.062), 
triglyceride levels (P=0.062) and pack-years smoked (P=0.13).  There was no appreciable 
impact of diabetes duration, or vascular factors (blood pressure, TcPO2) on the corneal nerve 
fibre length model by ethnicity.  
To further investigate the effect of smoking, we compared corneal nerve fibre length in never 
smokers, although numbers were small. The ethnic difference did not remain in this sub-group 
(age and HbA1C -adjusted estimated marginal means were 20.7 (17.9-23.5 [95% CI]) mm/mm
2 
(South Asian n=30) and 21.7 (18.0-25.3) mm/mm2 (European n=18); P=0.68). South Asian ex-
smokers, however, retained their high corneal nerve fibre length (21.2 (18.4–24.0) mm/mm2) 
whereas European ex-smokers had lower corneal nerve fibre length (17.8 (15.8-19.9) mm/mm2, 
P=0.053), despite the fact that pack-years smoked were not significantly different between 
these two sub-groups (P=0.55). 
The analysis for corneal nerve branch density by ethnicity showed similar results to corneal 
nerve fibre length. Variables with the greatest impact accounting for the ethnic difference in 
corneal nerve branch density estimated marginal means were pack-years smoked and BMI, 
changing the age- and HbA1C-adjusted means from 59.3 (50.7-68.8) [95% CI] no/mm
2 (South 
Asian) and 46.1 (39.1-53.8) no/mm2 (European), P=0.026 to 54.8 (45.6-65.1) no./mm2 (South 
Asian) and 45.0 (37.3-53.7) no./mm2 (European), P=0.13 for pack years smoked and to 58.0 
(49.4-67.6) no./mm2 (South Asian) and 47.1 (39.9-55.1) no./mm2 (European), P=0.076, for 
BMI.  
 
 
Explanations for ethnic differences in HRV-DB and sural nerve amplitude  
The multivariable regression analysis showed that ethnicity was not an independent statistically 
significant variable for HRV-DB (Table 4). Multivariable modelling of HRV-DB by ethnicity 
showed that after adjusting for age and hypertensive therapy, which were the independent 
statistically significant variables, BMI attenuated the ethnicity P-value most (Table 4). The 
adjusted means changed from 7.9 (6.9-8.9) beats/min. (South Asian) and 7.1 (6.1-8.2) 
beats/min. (European), P=0.27 to 7.7 (6.7-8.7) beats/min. (South Asian) and 7.2 (6.2-8.3) 
beats/min. (European), P=0.52. There was no appreciable impact of diabetes duration, 
glycaemia or triglyceride differences on the HRV-DB model by ethnicity. Pack-years smoked 
reduced the P-value of ethnicity in the age and hypertensive therapy adjusted model to 0.13; 
8.3 (7.2-9.4) beats/min. (South Asian) and 7.1 (6.1-8.3) beats/min. (European). 
BMI and hypertensive therapy appeared to have the greatest impact on the ethnic difference in 
sural nerve amplitude after adjusting for age and duration of the diabetes, the independent 
statistically significant variables for sural nerve amplitude. BMI changed the age and diabetes 
duration adjusted estimated marginal means for ethnicity from 10.1 (8.7-11.6) µV (South 
Asian) and 7.5 (6.3-8.7) µV (European), P=0.006 to 9.8 (8.5-11.3) µV (South Asian) and 7.7 
(6.5-9.0) µV (European), P=0.030 and hypertensive therapy changed them to 10.1 (8.6-11.8) 
µV (South Asian) and 8.1 (6.7-9.7) µV (European), P=0.068. There were no additional effects 
of glycaemia, vascular factors or triglycerides on the sural nerve amplitude model by ethnicity. 
The GAMs analyses appeared to show little difference in including spline functions for the 
continuous variables in the four outcome models. These analyses suggest that it is reasonable 
for the covariates to be modelled as linear variables in the regression. However, other 
functional forms should be considered in further studies as the lack of large differences between 
 
 
models with more complex relationships and the simple linear terms may be due to limited 
sample size and power. 
The Heckman selection models considered a number of variables as possible determinants of 
whether a participant was in the follow-up study and the impact this had on the outcome model. 
In three of the four models there was a lack of evidence that the selection model has any impact 
on the outcome model. For the sural nerve amplitude outcome, there did appear to be a 
relationship between whether a participant was included in the follow-up analyses and the 
outcome model. However, the three variables in the model all remained statistically significant 
at the 5% level and 1% level. The parameter coefficients changed minimally for ethnicity and 
age – both were less than 7% changed – but the duration of diabetes coefficients changed by 
27%, probably due to the duration of diabetes variable being significant in the selection model. 
Therefore, due to the small differences with the model that did not consider selection, and for 
consistency with the other outcomes, the results above for sural nerve amplitude are presented 
without adjustment for selection bias. 
  
 
 
Discussion 
In this detailed, primary care, population-based study, we show that South Asians with type 2 
diabetes in the UK have longer corneal nerve fibres and greater corneal nerve branch densities, 
i.e. better preserved structure of small nerve fibres, than equivalent Europeans. Despite low 
levels of clinical neuropathy in both of these community-based groups, South Asians also 
demonstrated better cardiac autonomic function during HRV-DB testing, indicating less small 
fibre neuropathy, compared with Europeans, plus some preservation of electrophysiological 
variables, supporting our previous findings from the original cohort12. This is the first report of 
a lower prevalence of small nerve fibre structural abnormalities in South Asian compared with 
European people with type 2 diabetes and may provide further evidence for a potential 
mechanism for the lower incidence of foot ulceration and amputation in South Asians 
compared to Europeans. We also show that classical risk factors for coronary heart disease, i.e. 
smoking, BMI and triglyceride levels, accounted for much of the structural differences in small 
nerve fibres between South Asians and Europeans, with negligible effects, surprisingly, from 
either vascular or glycaemic factors. Although the study was sufficiently powered to determine 
ethnic differences in corneal morphometric measures, a significant limitation of this study is 
that biopsy sample numbers (and therefore intra-epidermal nerve fibre density data) lacked 
power to support the corneal nerve findings. A further limitation was that cardiac autonomic 
neuropathy was only assessed using heart rate variability on deep breathing and did not include 
other measures including E:I index. 
Hyperglycaemia has consistently been shown to be a strong risk factor for diabetic peripheral 
neuropathy in epidemiological studies of people with type 1 and type 2 diabetes29-32. Of 
relevance, the large Eurodiab study showed that vascular risk factors are as important as 
glycaemic control in the development of diabetic neuropathy in people with type 1 diabetes29. 
In one of the few longitudinal studies assessing the development of neuropathy in type 2 
 
 
diabetes, a higher HbA1c and a lower fasting and post glucose serum insulin and paradoxically, 
lower systolic and diastolic blood pressure were associated with the development of 
neuropathy32. Our data supports our previous findings that the lower prevalence of small fibre 
neuropathy in our South Asian population is not explained by favourable HbA1c levels
12. 
Recently elevated triglycerides have been associated with the development of neuropathy in a 
cohort of people predominantly with type 2 diabetes33. Furthermore, obesity and 
hyperlipidaemia have also been shown to be important risk factors for early neuropathy in pre-
diabetes34. Thus our findings that lower levels of smoking and triglycerides were the major 
factors to explain the greater preservation of corneal nerve fibres in the South Asians supports 
these studies’ findings. Furthermore, the lower BMI of the South Asians (body fat measure) 
was also the main driver of ethnic differences in sural nerve amplitude (large fibre) and heart 
rate deep breathing (small, autonomic fibre). Weight and triglycerides are both indicators of 
adiposity and the imbalanced metabolic environment in obesity33, and therefore may be a proxy 
for other abnormal metabolic parameters such as oxidative stress or pro-inflammatory 
cytokines. One may argue that corneal nerve fibres do not represent peripheral nerve fibres 
regulating cutaneous blood flow, however, our recent study has shown that corneal confocal 
microscopy has comparable sensitivity and specificity to IENFD in the diagnosis of diabetic 
neuropathy35. Furthermore, we have also shown that a lower corneal nerve fibre length predicts 
incident clinical diabetic neuropathy in Type 1 diabetes36 and worsening glucose tolerance in 
subjects with impaired glucose tolerance37. 
The link between CCM and CAN is an important finding and CCM has also previously been 
shown to correlate significantly with sudomotor and cardiac autonomic neuropathy18-20. Here 
we also show a relationship between CCM and a measure of cardiac autonomic neuropathy. 
Previous studies have shown stronger associations between neuropathy and CCM 
abnormalities due to the inclusion of patients with more severe neuropathy. However, our 
 
 
patient cohort was recruited from primary care and most patients had no or mild neuropathy. 
This may also suggest that CAN may be an early manifestation of diabetic neuropathy.  
The identification of cardiovascular risk factors in attenuating the increased risk of small fibre 
neuropathy in Europeans vs. South Asians may provide potentially important therapeutic 
targets for a major end point of diabetes38. However, this needs to be verified in a prospective 
study. Furthermore, the altered pathophysiology of diabetic small fibre neuropathy, especially 
early neuronal changes, found here between Europeans and South Asians highlights the 
growing need for evidence-based medicine for treating diabetes in different ethnic groups7. 
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Table 1. Demographic and clinical characteristics of ethnic groups. 
 South Asians Europeans P-value  
n (M/F) 77 (51/26) 78 (45/33) 0.27 
Age (years) 61.2 ± 9.7 64.0 ± 8.0 0.047 
Duration diabetes (years)  11.9 (4.2-35.2) 10.3 (4.8-30.9) 0.063 
Height (m) 1.63 ± 0.10 1.66 ± 0.09 0.046 
Weight (kg) 80.1 ± 14.0 93.0 ± 17.3 <0.001 
BMI (kg/m2) 30.2 ± 5.2 33.6 ± 5.4 <0.001 
Waist (cm) 103.6 ±11.2 112.6 ± 12.1 <0.001 
Hips (cm) 103.0 ± 13.1 113.2 ± 12.3 <0.001 
Waist-to-hip ratio 0.99 (0.82-2.23) 0.99 (0.84-1.42) 0.78 
HbA % 
 
1c (%) 
7.8 (5.8-14.2) 7.3 (5.6-12.6) 
0.016 
 
HbA1c (mmol/mol) 62 (40-132) 57 (38-114) 
Total cholesterol (mmol/l) 3.8 (2.1-7.3) 4.0 (1.9-7.7) 0.34 
HDL-cholesterol (mmol/l) 1.1 ± 0.2 1.1 ± 0.4 0.49 
Triglycerides (mmol/l) 1.7 (0.6-5.2) 2.2 (0.8-7.9) 0.001 
Fibrinogen (g/l) 3.6 (2.1-7.6) 3.7 (1.9-5.6) 0.42 
Retinopathy (%) 22/64 (34) 21/52 (29) 0.48 
Nephropathy (%) 9/62 (15) 5/75 (7) 0.13 
Myocardial Infarction (%) 12/69 (17) 12/75 (16) 0.82 
Angina (%) 19/64 (30) 15/74 (20) 0.20 
Coronary artery bypass graft (%) 13/70 (19) 11/74 (15) 0.55 
Resting Heart Rate (bpm) 75.7 ± 14.3 74.9 ± 12.6 0.72 
Systolic blood pressure (mmHg) 132.8 ± 16.2 135.8 ± 16.6 0.26 
Diastolic blood pressure (mmHg) 72.2 ± 9.8 70.4 ± 9.3 0.27 
TcPO2 (mmHg) 62.0 ± 9.9 57.7 ± 12.6 0.019 
Peripheral arterial disease (%)  5/58 (9) 15/74 (20) 0.064 
Peripheral vascular surgery 2/67 (3) 6/69 (9) 0.27 
Pack-years smoked (n)* 0, 0-14.9 (0-78) 
10.5, 0-31 (0-
99) 
0.006 
Insulin therapy (%) 14/69 (20) 20/67 (30) 0.20 
Oral antidiabetic drugs (%) 64/69 (93) 62/68 (91) 0.73 
Antihypertensive drugs (%) 45/69 (65) 54/67 (81) 0.044 
Statin therapy (%) 53/68 (78) 59/66 (89) 0.074 
Data are % prevalence, means ± SD, or geometric means (range). 
*Data presented as median, IQR (range) 
 
TcPO2, transcutaneous partial pressure of oxygen. 
 
 
Table 2. Measures of neuropathy signs, symptoms, nerve fibre function, corneal nerve fibre 
structure and intra epidermal nerve fibre density by ethnicity. 
 
Neuropathy Variables South Asian European 
 
P-
Value* 
 
Neuropathy signs    
Neuropathy Disability Score (0-10)** 2, 1-6 (0-10) 3, 1.8-6 (0-10) 0.50 
Vibration Perception Threshold (Volts) 12.2 (2.5-40.7) 14.2 (3.7-50.0) 0.16 
Neuropathy symptoms    
Neuropathy Symptoms and Change  (0-38) 4, 2-11 (0-23) 4, 2-9 (0-23) 0.57 
McGill Dimension of Pain (0-5)** 1, 0-2 (0-4) 1, 0-2 (0-5) 0.77 
McGill Visual Analogue Score (0-10)** 4, 0-6.3 (0-10) 3, 0-6 (0-10) 0.19 
McGill Total pain rating index (0-60)** 8, 1-19 (0-41) 
7.5, 2-16.5 (0-
49) 
0.92 
Painful neuropathy (%) 30/75 (40) 36/77 (47) 0.40 
Painful symptoms, without neuropathy (%) 31/75 (41) 18/77 (23) 0.018 
Functional measures    
Sural nerve conduction velocity (m/s) 45.3 ± 7.1 45.2 ± 6.8 0.95 
Sural Amplitude (µV) 10.0 (1.3-43.0) 7.2 (1.0-30.0) 0.006 
Peroneal nerve conduction velocity (m/s) 44.7 ± 5.5 44.4 ± 6.0 0.74 
Peroneal nerve Amplitude (mV)** 
3.3, 1.6-5.3 (0.1-
43.0) 
2.6, 1.7-4.5 
(0.1-7.4) 
0.25 
Peroneal nerve F wave latency (m/s) 51.0 ± 7.2 53.0 ± 5.9 0.091 
    
Heart rate variability deep breathing (bpm) 7.9 (1.4-27.7) 6.5 (1.5-22.0) 0.044 
Neuropad colour change (%)** 
68.8, 30.6-95.0 
(0-100) 
55.0, 15.0-87.5 
(0-100) 
0.11 
Cold Sensation threshold (°C)** 
25.9, 23.1-27.7 
(1.4-30.2) 
25.6, 22.9-27.2 
(0-30.3) 
0.30 
Warm Sensation threshold (°C) 41.6 ± 4.2 42.0 ± 3.8 0.53 
Cold Induced Pain (°C)** 
1.9, 0-9.4 (0-
23.0) 
1.3, 0-5.9 (0-
21.6) 
0.31 
 
 
Heat Induced Pain (°C)** 
49.1, 46.8-50.0 
(42.7-50.0) 
49.0, 47.4-49.9 
(44.4-50.0) 
0.80 
Corneal confocal morphometry 
 
   
Corneal nerve fibre length (mm/mm2) 22.0 ± 7.9 19.3 ±6.3 0.037 
Corneal nerve fibre density (no/mm2) 24.7 ± 8.2 25.1 ± 7.4 0.76 
Corneal nerve branch density (no/mm2) 60.0 (4.7-246.2) 
46.0 (3.1-
129.2) 
0.021 
Corneal nerve fibre tortuosity coefficient 18.7 ± 4.7 20.1 ± 6.2 0.16 
Intra-epidermal nerve fibre density (no/mm2) 2.9 (0.5-7.5) 2.1 (0.2-6.5) 0.14 
Data are % prevalence, means ± SD, or geometric means (range). 
*P value for ethnic difference. 
**Data presented as median, IQR (range) 
 
  
 
 
Table 3. Multivariable regression analysis and attenuation information for corneal nerve fibre 
length. 
Statistically significant variables chosen in the backward step-wise selection procedure for 
corneal nerve fibre length. This procedure includes all neuropathy risk factors in the 
regression model and then removes the least significant variable, runs the regression model 
again and repeats these steps until only variables significant at the 5% level remain in the 
model.   
Variables Parameter estimates (95% CI) P Value 
Ethnicity 
(Asian compared to white) 
2.593 (0.225, 4.961) 0.032 
Age (per year) -0.198 (-0.331, -0.065) 0.004 
HbA1c (per unit) -1.531 (-2.380, -0.682) <0.001 
 
 
Difference in corneal nerve fibre 
length based on ethnicity only 
(unadjusted), the difference based 
on ethnicity after adjusting for age 
and HbA1c, and the difference 
based on ethnicity after adjusting 
for age, HbA1c and one additional 
specified variable. 
Estimated marginal means for ethnicity 
(95% CI) 
 
Adjustment variables South Asian European P Value 
for 
ethnicity 
Unadjusted 22.0 (20.2-23.7) 19.3 (17.6-21.0) 0.037 
 
Adjustment for age and HbA1c: 
Age (p=0.004) + HbA1c (p<0.001) 21.9 (20.2-23.6) 19.3 (17.7-20.9) 0.032 
 
Adjustment for age, HbA1c and variable listed: 
Duration of diabetes (p=0.51) 22.2 (20.4-23.9) 19.3 (17.6-21.0) 0.023 
BMI (p=0.33) 22.0 (20.1-23.8) 19.5 (17.7-21.3) 0.062 
Triglycerides (p=0.68) 21.8 (20.0-23.5) 19.4 (17.7-21.0) 0.062 
Diastolic BP (p=0.99) 21.9 (20.2-23.6) 19.3 (17.7-20.9) 0.033 
TcPO2 (p=0.47) 21.9 (20.2-23.7) 19.2 (17.6-20.9) 0.027 
Pack-Years Smoked (p=0.39) 21.0 (19.1-22.9) 18.9 (17.1-20.7) 0.13 
Hypertensive therapy (p=0.62) 21.7 (19.9-23.5) 18.7 (16.8-20.6) 0.021 
 
 
 
P-value in parentheses shows significance of adjustment factor in the regression model. 
TcPO2, transcutaneous partial pressure of oxygen. 
N=130 for unadjusted, N=125-129 for all other analyses except pack years smoked where 
N=106, hypertensive where N=113 and smoking status where N=113 
  
 
 
Table 4. Multivariable regression analysis and attenuation information for heart rate 
variability to deep breathing. 
 
Statistically significant variables chosen in the backward stepwise selection procedure for 
heart rate variability to deep breathing. This procedure includes all neuropathy risk factors in 
the regression model and then removes the least significant variable, runs the regression 
model again and repeats these steps until only variables significant at the 5% level remain in 
the model. 
Variables 
Parameter estimates* (95% 
CI) 
P Value 
Age (per year) -0.019 (-0.025, -0.012) <0.001 
Hypertensive therapy 
(Yes compared to No) 
-0.186 (-0.306, -0.066) 0.003 
*These are on the natural logarithm scale of (HRDB plus 5) i.e. each increase in age is related 
to a decrease of 0.019 in the natural logarithm of (HRDB plus 5). 
 
Difference in heart rate variability to deep breathing based on ethnicity only (unadjusted), the 
difference based on ethnicity after adjusting for age and HbA1c, and the difference based on 
ethnicity after adjusting for age, HbA1c and one additional specified variable. 
 
 Estimated marginal means for ethnicity 
(95% CI) 
 
Adjustment variables South Asian European P Value 
for 
ethnicity 
Unadjusted 7.9 (6.9-9.0) 6.5 (5.6-7.5) 0.044 
 
Adjustment for age and hypertensive therapy: 
Age (p<0.001) + Hypertensive 
therapy (p=0.005) 
7.9 (6.9-8.9) 7.1 (6.1-8.2) 0.27 
 
Adjustment for age, hypertensive therapy and variable listed: 
Duration of diabetes (p=0.36) 8.0 (7.0-9.1) 7.0 (6.0-8.2) 0.18 
BMI (p=0.15) 7.7 (6.7-8.7) 7.2 (6.2-8.3) 0.52 
HbA1c (p=0.27) 7.9 (7.0-9.0) 7.0 (6.1-8.1) 0.19 
Triglycerides (p=0.80) 7.9 (6.9-8.9) 7.1 (6.1-8.2) 0.30 
Diastolic BP (p=0.072) 7.9 (7.0-8.9) 7.2 (6.2-8.2) 0.28 
 
 
TcPO2 (p=0.25) 7.8 (6.9-8.8) 7.1 (6.2-8.2) 0.32 
Pack-Years Smoked (p=0.78) 8.3 (7.2-9.4) 7.1 (6.1-8.3) 0.13 
P-value in parentheses shows significance of adjustment factor in the regression model. 
TcPO2, transcutaneous partial pressure of oxygen. 
N=135 for unadjusted, N=116-118 for all other analyses except pack years smoked where 
N=97 and smoking status where N=103. 
 
